Please note that the ANZCTR website will be unavailable from 9am until 9.30am (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00483548




Registration number
NCT00483548
Ethics application status
Date submitted
5/06/2007
Date registered
7/06/2007
Date last updated
23/02/2010

Titles & IDs
Public title
Adjunctive Ziprasidone in the Treatment of Bipolar I Depression
Scientific title
A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression
Secondary ID [1] 0 0
A1281158
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bipolar Disorder 0 0
Depression, Bipolar 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Depression
Mental Health 0 0 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ziprasidone
Treatment: Drugs - Placebo

Experimental: Ziprasidone - Active treatment, double-blind, randomized treatment arm

Placebo Comparator: Placebo - Inactive, placebo treatment, double-blind, randomized arm


Treatment: Drugs: Ziprasidone
Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.

Treatment: Drugs: Placebo
Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Timepoint [1] 0 0
Baseline, Week 6
Secondary outcome [1] 0 0
Change From Baseline to Week 6 in Clinical Global Impression - Severity Scale (CGI-Severity or CGI-S)
Timepoint [1] 0 0
Baseline, Week 6
Secondary outcome [2] 0 0
MADRS Remission: Number of Subjects With Total MADRS Score = 12 at Week 6
Timepoint [2] 0 0
Week 6
Secondary outcome [3] 0 0
MADRS Response: Number of Subjects With Total MADRS Score Reduction = 50 Percent From Baseline at Week 6
Timepoint [3] 0 0
Week 6
Secondary outcome [4] 0 0
Clinical Global Impression - Improvement Scale (CGI-Improvement or CGI-I): Number of Subjects With Response (Much Improved or Very Much Improved) at Week 6
Timepoint [4] 0 0
Baseline, Week 6
Secondary outcome [5] 0 0
Change From Baseline in MADRS Total Score (Post-baseline Excluding Week 6)
Timepoint [5] 0 0
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
Secondary outcome [6] 0 0
Change From Baseline in CGI-Severity Score (Post-baseline Excluding Week 6)
Timepoint [6] 0 0
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
Secondary outcome [7] 0 0
CGI-Improvement Score
Timepoint [7] 0 0
Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Secondary outcome [8] 0 0
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score
Timepoint [8] 0 0
Baseline, Week 2, Week 4, Week 6
Secondary outcome [9] 0 0
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
Timepoint [9] 0 0
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Secondary outcome [10] 0 0
Change From Baseline in Global Assessment of Functioning (GAF) Scale at Week 6
Timepoint [10] 0 0
Baseline, Week 6
Secondary outcome [11] 0 0
Change From Baseline in Sheehan Disability Scale (SDS) at Week 6 (Items 1 Through 3)
Timepoint [11] 0 0
Baseline, Week 6
Secondary outcome [12] 0 0
Change From Baseline in Sheehan Disability Scale (SDS) at Week 6 (Items 4 and 5)
Timepoint [12] 0 0
Baseline, Week 6
Secondary outcome [13] 0 0
Change From Baseline in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Scores at Week 6
Timepoint [13] 0 0
Baseline, Week 6

Eligibility
Key inclusion criteria
- Adults meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria for Bipolar I disorder, most recent episode depressed, with or
without rapid cycling and without psychotic features. Subjects receive therapeutic
dose of lithium, valproate or lamotrigine for at least 4 weeks prior to randomization.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with ultra-fast rapid cycling (8 or more mood episodes per year)

- Significant heart disease including abnormalities in the heart's rhythm (QT
prolongation)

- Psychotic symptoms (hallucinations and/or delusions).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Pfizer Investigational Site - Westmead
Recruitment hospital [2] 0 0
Pfizer Investigational Site - Everton Park
Recruitment hospital [3] 0 0
Pfizer Investigational Site - Spring Hill
Recruitment hospital [4] 0 0
Pfizer Investigational Site - Richmond
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
4053 - Everton Park
Recruitment postcode(s) [3] 0 0
4000 - Spring Hill
Recruitment postcode(s) [4] 0 0
3121 - Richmond
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Hampshire
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Washington
Country [26] 0 0
United States of America
State/province [26] 0 0
Wisconsin
Country [27] 0 0
India
State/province [27] 0 0
Ahmedabad
Country [28] 0 0
India
State/province [28] 0 0
Gujarat
Country [29] 0 0
India
State/province [29] 0 0
Maharashtra
Country [30] 0 0
India
State/province [30] 0 0
New Delhi

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine if a treatment regimen of ziprasidone plus a mood
stabilizer is safe and effective in the short term treatment of Bipolar I Depression.
Ziprasidone will be added to lithium, valproate or lamotrigine after the patient has been on
a therapeutic dose of one of these mood stabilizers for at least 4 weeks.
Trial website
https://clinicaltrials.gov/show/NCT00483548
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications